Abstract

The hepatitis C virus is a viral disease that causes cirrhosis and hepatocellular carcinoma in the liver. Since the virus's discovery, significant therapeutic advances have been made. Notwithstanding, its upsurge necessitates the development of novel approaches to combating this disease. Recent studies have seen a rise in the value of plant compounds in the establishment of novel, efficient, and cost-efficient anti-HCV medications. These factors have motivated us to continuously search for novel, potent anti-HCV inhibitors, ideally with mechanisms different from those used in conventional medicine. Several filtrations processes including ADMET, molecular docking, and molecular dynamics (MD) simulation were used to choose potent hits from plant molecules deposited in the PubChem database. The binding kinetics were explored using MD simulation studies performed for 100 ns using GROMACS-2018.1. which was done to validate and supplement the findings of the virtual screening. The selected hits (with PubChem CID of 3,560,948 and 4,754,183) had preferable molecular traits that suggested they might work well as HCV inhibitors and are term as effective potential hits. The MD study confirmed the stability of the identified hit with a binding energy of −111.724 ( ± 81.668) kj/mol and mechanisms different from the FDA-approved drug (sofosbuvir) used as a reference with a binding energy of −106.132 ( ± 78.008) kj/mol. This approach could aid in the establishment and identification of novel inhibitors in pharmaceutical discovery. Experimental assessments could indeed ascertain as to if the identified molecule can be employed as an anti-HCV drug to address the ailment and confirm the reliability of our in-silico studies.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.